Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

711 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Maeda H, et al. Among authors: sawa t. J Control Release. 2000 Mar 1;65(1-2):271-84. doi: 10.1016/s0168-3659(99)00248-5. J Control Release. 2000. PMID: 10699287 Review.
SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours.
Greish K, Sawa T, Fang J, Akaike T, Maeda H. Greish K, et al. Among authors: sawa t. J Control Release. 2004 Jun 18;97(2):219-30. doi: 10.1016/j.jconrel.2004.03.027. J Control Release. 2004. PMID: 15196749
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Fang J, Sawa T, Akaike T, Greish K, Maeda H. Fang J, et al. Among authors: sawa t. Int J Cancer. 2004 Mar;109(1):1-8. doi: 10.1002/ijc.11644. Int J Cancer. 2004. PMID: 14735461
PEG-ZnPP-treated SW480 cells became vulnerable to insults caused by various cytotoxic agents; the 50% lethal doses were reduced by 25%, 39%, 83%, and 61% for hydrogen peroxide, t-butyl hydroperoxide, camptothecin and doxorubicin, respectively. ...
PEG-ZnPP-treated SW480 cells became vulnerable to insults caused by various cytotoxic agents; the 50% lethal doses were reduced by 25%, 39%, …
Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium.
Tanaka S, Akaike T, Wu J, Fang J, Sawa T, Ogawa M, Beppu T, Maeda H. Tanaka S, et al. Among authors: sawa t. J Drug Target. 2003 Jan;11(1):45-52. doi: 10.1080/1061186031000086072. J Drug Target. 2003. PMID: 12852440
In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor.
Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A, Maeda H. Fang J, et al. Among authors: sawa t. Cancer Res. 2003 Jul 1;63(13):3567-74. Cancer Res. 2003. PMID: 12839943
Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J, Sawa T, Maeda H. Fang J, et al. Among authors: sawa t. Adv Exp Med Biol. 2003;519:29-49. doi: 10.1007/0-306-47932-X_2. Adv Exp Med Biol. 2003. PMID: 12675206 Review.
Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide.
Fang J, Sawa T, Akaike T, Maeda H. Fang J, et al. Among authors: sawa t. Cancer Res. 2002 Jun 1;62(11):3138-43. Cancer Res. 2002. PMID: 12036926
Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue.
Sawa T, Wu J, Akaike T, Maeda H. Sawa T, et al. Cancer Res. 2000 Feb 1;60(3):666-71. Cancer Res. 2000. PMID: 10676651
Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity.
Sahoo SK, Sawa T, Fang J, Tanaka S, Miyamoto Y, Akaike T, Maeda H. Sahoo SK, et al. Among authors: sawa t. Bioconjug Chem. 2002 Sep-Oct;13(5):1031-8. doi: 10.1021/bc020010k. Bioconjug Chem. 2002. PMID: 12236785
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H, Sawa T, Konno T. Maeda H, et al. Among authors: sawa t. J Control Release. 2001 Jul 6;74(1-3):47-61. doi: 10.1016/s0168-3659(01)00309-1. J Control Release. 2001. PMID: 11489482 Review.
711 results
Jump to page
Feedback